Health Care/Hospital

Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia

* SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs inSingapore, with launch planned in Singapore in the first quarter of 2022 followed by expansion in conjunction with SAGE Healthcar...

2021-12-16 21:00 2575

Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...

2021-12-16 21:00 2447

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

TAIZHOU, China, Dec. 16, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"),(NASDAQ: SXTC) announced today that on December 14, 2021, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notif...

2021-12-16 21:00 1525

Launching the world's first all-in-one medical and welfare VR platform JOLLYGOOD+

TOKYO, Dec. 16, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good") will begin providing JOLLYGOOD+, an all-in-one medical and welfare VR platform that integrates medical education VR for medical staff training, nursing care training VR, social skills training (SST) VR, and recreational VR.

2021-12-16 21:00 1560

Senhwa Clinical Data Abstract for Silmitasertib in Patients with Advanced Basal Cell Carcinoma Accepted for 2022 AAD Annual Meeting

TAIPEI and SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting preliminary clinical data for their lead drug...

2021-12-16 20:00 1756

Bionomics Limited Announces Pricing of Initial Public Offering in the United States

ADELAIDE, Australia, Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited (Bionomics orCompany), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering inthe United States (the Offering) of 1,622,000 American Depositary Shares (ADSs), each representing 1...

2021-12-16 19:00 2278

Akso Health Group Announces Effective Date of Name Change and Ticker Symbol Change

BEIJING, Dec. 16, 2021 /PRNewswire/ -- Akso Health Group ("Akso Health", the "Company" or "We") (NASDAQ: AHG), formerly known as Xiaobai Maimai Inc., today announced that the Company will update its name and ticker symbol on the Nasdaq Stock Market, effective at the start of trading onDecember 16...

2021-12-16 19:00 2292

Health insurance "bargaining": Every cent for life and health

BEIJING, Dec. 16, 2021 /PRNewswire/ -- An interview with reporter Sun Wanlu from China.org.cn onChina's Health insurance "bargaining":   3-year-olds are called toddlers who should be jumping around and creating trouble all over the place. But Songzi, a toddler born with spinal m...

2021-12-16 17:22 1395

Statement by WuXi AppTec Regarding Recent Market Fluctuation

SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the world. We will provide any new information as warranted and in compliance with applicable laws and regulations...

2021-12-16 08:00 2317

SQREEM's New AI-powered Study Examines Motivations Surrounding COVID-19 Vaccine Resistance in the US

NEW YORK, Dec. 15, 2021 /PRNewswire/ -- COVID-19 vaccines have once again become a hot topic inthe United States as President Joe Biden pushes on with vaccination mandates in a bid to manage concerns around the Omicron variant ahead of the winter flu season. Despite vaccination ratesreaching  60%...

2021-12-15 22:00 1376

FDA Breakthrough Devices Designation Application to Fast-Track Painful Finger-Prick Alternative for People Living with Diabetes

SYDNEY, Dec. 15, 2021 /PRNewswire/ -- Life Science Biosensor Diagnostics Pty Ltd (LSBD), a life sciences and medical technology company and subsidiary of The iQ Group Global, announced it has filed an application with the U.S Food and Drug Administration (FDA) for Breakthrough Devices Designation...

2021-12-15 21:01 1220

I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China

SHANGHAI and GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- I-Mab  (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) ofChina's Na...

2021-12-15 21:00 1307

Red Seal brings New Zealand's #1 best-selling herbal and mineral toothpaste to Pharmaca Integrative Pharmacies, USA

AUCKLAND, New Zealand, Dec. 14, 2021 /PRNewswire/ -- Wednesday 14 December, 2021 , Red Seal is proud to announce their herbal and mineral toothpastes are now conveniently available at all 28 distinguished Pharmaca stores nationwide.  www.redseal.global/usa Pharmaca...

2021-12-15 10:41 1606

Limbach Group adopts QuantaMatrix dRAST™ in routine clinical use

* QuantaMatrix's direct Rapid Antimicrobial Susceptibility Testing system (dRAST) improves optimal prescription of antibiotics by two days comparedto conventional methods * Following successful validation of dRAST platform in Europe at key reference laboratories, system now adopted for clinica...

2021-12-15 07:39 1376

Info-Tech Research Group Reveals 2022 Tech Trends

SYDNEY, Dec. 15, 2021 /PRNewswire/ -- Info-Tech Research Group, one of the fastest-growing information technology and research advisory firms in the world, has revealed its annual tech trend insights for the coming year. Info-Tech offers research, diagnostics, and workshops to systematically impr...

2021-12-15 06:00 2262

Cochl joins ABB's innovation growth hub SynerLeap for audio-based anomaly detection and emergency monitoring

SAN JOSE, Calif., Dec. 14, 2021 /PRNewswire/ -- Cochl has become a member of Synerleap, ABB's innovation growth hub located in the heart of the ABB's Head Office in VästeråsSweden. Synerleap aims to create an ecosystem where ABB can utilize and enable technology companies to grow and expand on a ...

2021-12-15 01:00 1742

ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety

SUZHOU, China, and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from three ...

2021-12-14 22:04 2045

ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses

SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from six st...

2021-12-14 22:04 2029

Jolly Good launches R&D of VR therapy for chronic pain with Aichi Medical University's Pain Center.

TOKYO, Dec. 14, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good"), in collaboration with Aichi Medical University Hospital's Pain Center ("Aichi Medical University"), the first interdisciplinary treatment and research facility for pain inJapan, will research the efficacy of VR therapy for chron...

2021-12-14 21:00 1310

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

MELBOURNE, Australia, Dec. 14, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that the New Zealand Medicines and Medic...

2021-12-14 20:25 1549
1 ... 146147148149150151152 ... 256